CLLS Stock Analysis: Buy, Sell, or Hold?
CLLS - Cellectis S.A. American Depositary Shares
$3.30
0.36 (12.24%)
▲
5d:
+14.19%
30d:
-2.37%
90d:
-2.37%
BUY
HIGH Confidence
Analysis Updated: Jul 2, 2026 12:00 AM ET
Earnings: Aug 03, 2026
30d
Get Alerted When CLLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: CLLS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: CLLS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: CLLS is currently trading at $3.30, which is considered slightly high relative to its 30-day fair value range of $2.87 to $3.39.
Technical Outlook: Technically, CLLS is in a downtrend. The price is approaching resistance at $3.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.2% recently.
Market Sentiment: CLLS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.60 (+130.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CLLS is in a downtrend. The price is approaching resistance at $3.19. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 12.2% recently.
Market Sentiment: CLLS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $7.60 (+130.3%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$2.87 -
$3.39
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.2%)
- BULLISH: Trading 130.3% below Wall St target ($7.60)
Trading Range Analysis
30-Day Trading Range
$2.87 -
$3.39
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.70
Resistance Level
$3.19
Current Trend
Downtrend
Technical data as of
Jul 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.73
Wall Street Target
$7.60
(+130.3%)
Revenue Growth (YoY)
-37.3%
Profit Margin
-89.5%
Share & Embed Analysis
Last updated: July 03, 2026 12:42 AM ET
Data refreshes hourly during market hours. Next update: 1:42 AM
Data refreshes hourly during market hours. Next update: 1:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CLLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 55 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 59 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 63 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 54 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 63 BUY |
